instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the administration route of drug 'PREDNISOLONE'? | Recurrence and Outcome of Anti-Glomerular Basement Membrane Glomerulonephritis After Kidney Transplantation.
Recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis in the kidney graft is a rare event, described in limited reports. The aim of this study was to evaluate, in a large cohort of patien... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 34307983 | 20,029,990 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19'. | Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report.
Reactivation or reinfection cases of SARS-CoV-2 are known but there is scarce evidence about reactivation in immunocompromised patients. Here, we report the case of ... | CYCLOPHOSPHAMIDE, DECITABINE, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TACROLIMUS, TOZINAMERAN, VENETOCLAX | DrugsGivenReaction | CC BY | 34308258 | 20,174,941 | 2021-07-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection reactivation'. | Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report.
Reactivation or reinfection cases of SARS-CoV-2 are known but there is scarce evidence about reactivation in immunocompromised patients. Here, we report the case of ... | CYCLOPHOSPHAMIDE, DECITABINE, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TACROLIMUS, TOZINAMERAN, VENETOCLAX | DrugsGivenReaction | CC BY | 34308258 | 20,174,941 | 2021-07-20 |
What was the dosage of drug 'DECITABINE'? | Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report.
Reactivation or reinfection cases of SARS-CoV-2 are known but there is scarce evidence about reactivation in immunocompromised patients. Here, we report the case of ... | 11 CYCLES | DrugDosageText | CC BY | 34308258 | 20,174,941 | 2021-07-20 |
What was the dosage of drug 'VENETOCLAX'? | Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report.
Reactivation or reinfection cases of SARS-CoV-2 are known but there is scarce evidence about reactivation in immunocompromised patients. Here, we report the case of ... | UNK (11 CYCLES) | DrugDosageText | CC BY | 34308258 | 20,174,941 | 2021-07-20 |
What was the outcome of reaction 'COVID-19'? | Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report.
Reactivation or reinfection cases of SARS-CoV-2 are known but there is scarce evidence about reactivation in immunocompromised patients. Here, we report the case of ... | Recovered | ReactionOutcome | CC BY | 34308258 | 20,174,941 | 2021-07-20 |
What was the outcome of reaction 'Infection reactivation'? | Possible Reactivation of SARS-CoV-2 in a Patient with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Case Report.
Reactivation or reinfection cases of SARS-CoV-2 are known but there is scarce evidence about reactivation in immunocompromised patients. Here, we report the case of ... | Recovered | ReactionOutcome | CC BY | 34308258 | 20,174,941 | 2021-07-20 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Urosepsis'. | Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study.
To monitor long-term outcomes of ocrelizumab treatment.
To evaluate safety and treatment outcomes of ocrelizumab in a community-based multiple sclerosis (MS) population.
Adult patients wit... | OCRELIZUMAB | DrugsGivenReaction | CC BY-NC | 34308352 | 19,639,946 | 2021 |
What was the administration route of drug 'OCRELIZUMAB'? | Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study.
To monitor long-term outcomes of ocrelizumab treatment.
To evaluate safety and treatment outcomes of ocrelizumab in a community-based multiple sclerosis (MS) population.
Adult patients wit... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34308352 | 19,639,946 | 2021 |
What was the outcome of reaction 'Urosepsis'? | Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study.
To monitor long-term outcomes of ocrelizumab treatment.
To evaluate safety and treatment outcomes of ocrelizumab in a community-based multiple sclerosis (MS) population.
Adult patients wit... | Fatal | ReactionOutcome | CC BY-NC | 34308352 | 19,639,946 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute respiratory distress syndrome'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Febrile neutropenia'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal fistula'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal perforation'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemorrhage'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ileus'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mucosal inflammation'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Palmar-plantar erythrodysaesthesia syndrome'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Proteinuria'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pulmonary embolism'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Venous thrombosis'. | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, IRINOTECAN, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34308512 | 19,685,690 | 2021-11 |
What was the dosage of drug 'BEVACIZUMAB'? | The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer.
BACKGROUND
Despite being widely used, to date (June 2021), the regimen of bevacizumab 10 mg/kg every 2 weeks (Q2W) combined with chemotherapy is not approved in Japan for patients w... | ADMINISTERED ON A FLEXIBLE SCHEDULE EVERY 3 OR 4 WEEKS ACCORDING TO THE CONDITION OF THE PATIENT | DrugDosageText | CC BY | 34308512 | 19,685,690 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bone disorder'. | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bone erosion'. | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mobility decreased'. | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pain in extremity'. | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pain'. | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, LEUCOVORIN CALCIUM, OXALIPLATIN | DrugsGivenReaction | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
What was the outcome of reaction 'Bone disorder'? | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | Recovered | ReactionOutcome | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
What was the outcome of reaction 'Bone erosion'? | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | Recovered | ReactionOutcome | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
What was the outcome of reaction 'Metastases to bone'? | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | Recovered | ReactionOutcome | CC BY-NC | 34308691 | 19,789,095 | 2021-07 |
What was the outcome of reaction 'Mobility decreased'? | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | Recovered | ReactionOutcome | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
What was the outcome of reaction 'Pain in extremity'? | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | Recovered | ReactionOutcome | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
What was the outcome of reaction 'Pain'? | Colorectal cancer with first known case of simultaneous bilateral tibial metastases.
The most common osseous metastatic regions for colorectal cancer are the lumbar and sacral vertebrae and the pelvis. There are few reported cases of isolated solitary tibial metastasis, and simultaneous bilateral solitary tibial metast... | Recovered | ReactionOutcome | CC BY-NC | 34308691 | 19,747,085 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated lung disease'. | Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer.
Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malign... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC | 34308703 | 19,701,322 | 2021 |
What was the dosage of drug 'PEMBROLIZUMAB'? | Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer.
Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malign... | UNK, EVERY 3 WEEKS; CYCLES | DrugDosageText | CC BY-NC | 34308703 | 19,701,322 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic cancer'. | The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
BACKGROUND
To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negati... | LENVATINIB, RAMUCIRUMAB, SORAFENIB | DrugsGivenReaction | CC BY | 34309225 | 19,739,609 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
BACKGROUND
To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negati... | LENVATINIB, RAMUCIRUMAB, SORAFENIB | DrugsGivenReaction | CC BY | 34309225 | 19,739,609 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to lung'. | The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
BACKGROUND
To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negati... | LENVATINIB, RAMUCIRUMAB, SORAFENIB | DrugsGivenReaction | CC BY | 34309225 | 19,739,609 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastasis'. | The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
BACKGROUND
To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negati... | LENVATINIB, RAMUCIRUMAB, SORAFENIB | DrugsGivenReaction | CC BY | 34309225 | 19,739,609 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
BACKGROUND
To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negati... | LENVATINIB, RAMUCIRUMAB, SORAFENIB | DrugsGivenReaction | CC BY | 34309225 | 19,739,609 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Weight increased'. | The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
BACKGROUND
To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negati... | LENVATINIB, RAMUCIRUMAB, SORAFENIB | DrugsGivenReaction | CC BY | 34309225 | 19,739,609 | 2021-07-26 |
What was the administration route of drug 'SORAFENIB'? | The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
BACKGROUND
To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negati... | Oral | DrugAdministrationRoute | CC BY | 34309225 | 19,739,609 | 2021-07-26 |
What was the dosage of drug 'LENVATINIB'? | The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
BACKGROUND
To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negati... | 8 MG | DrugDosageText | CC BY | 34309225 | 19,739,609 | 2021-07-26 |
What was the dosage of drug 'RAMUCIRUMAB'? | The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.
BACKGROUND
To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negati... | 8 MG | DrugDosageText | CC BY | 34309225 | 19,739,609 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Glioblastoma (GBM) is an exceptionally aggressive brain tumor with a dismal prognosis, demanding fast and precise classification as a base for patient-specific tre... | TEMOZOLOMIDE, VALPROIC ACID | DrugsGivenReaction | CC BY | 34309720 | 20,811,979 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm recurrence'. | Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Glioblastoma (GBM) is an exceptionally aggressive brain tumor with a dismal prognosis, demanding fast and precise classification as a base for patient-specific tre... | TEMOZOLOMIDE, VALPROIC ACID | DrugsGivenReaction | CC BY | 34309720 | 20,811,979 | 2021-07-26 |
What was the administration route of drug 'TEMOZOLOMIDE'? | Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Glioblastoma (GBM) is an exceptionally aggressive brain tumor with a dismal prognosis, demanding fast and precise classification as a base for patient-specific tre... | Oral | DrugAdministrationRoute | CC BY | 34309720 | 20,811,979 | 2021-07-26 |
What was the administration route of drug 'VALPROIC ACID'? | Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Glioblastoma (GBM) is an exceptionally aggressive brain tumor with a dismal prognosis, demanding fast and precise classification as a base for patient-specific tre... | Oral | DrugAdministrationRoute | CC BY | 34309720 | 20,811,979 | 2021-07-26 |
What was the dosage of drug 'VALPROIC ACID'? | Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Glioblastoma (GBM) is an exceptionally aggressive brain tumor with a dismal prognosis, demanding fast and precise classification as a base for patient-specific tre... | 300 MILLIGRAM/SQ. METER, DAILY, IN 2 DAILY | DrugDosageText | CC BY | 34309720 | 20,811,979 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | AMPHOTERICIN B, DEXAMETHASONE SODIUM PHOSPHATE | DrugsGivenReaction | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rhinocerebral mucormycosis'. | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | DEXAMETHASONE | DrugsGivenReaction | CC BY-NC-ND | 34310559 | 19,747,284 | 2021-07-26 |
What was the dosage of drug 'AMPHOTERICIN B'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | UNKNOWN | DrugDosageText | CC BY-NC-ND | 34310559 | 19,722,523 | 2021-07-26 |
What was the dosage of drug 'DEXAMETHASONE SODIUM PHOSPHATE'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | 4 mg (milligrams). | DrugDosage | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Condition aggravated'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Exophthalmos'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Herpes virus infection'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Hyperglycaemic hyperosmolar nonketotic syndrome'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Hypokalaemia'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Mental disorder'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Mucormycosis'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Ophthalmoplegia'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Rhinocerebral mucormycosis'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,747,284 | 2021-07-26 |
What was the outcome of reaction 'Septic shock'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Staphylococcal infection'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Stenotrophomonas infection'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
What was the outcome of reaction 'Visual impairment'? | A Rare Case of Invasive Mucormycosis in a Diabetic Patient Treated with a Short Course of Dexamethasone.
BACKGROUND Invasive mucormycosis is a rare, life-threatening infection that requires urgent medical management. Here we describe a patient who developed invasive mucormycosis after receiving only a short course of d... | Recovered | ReactionOutcome | CC BY-NC-ND | 34310559 | 19,723,528 | 2021-07-26 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Stevens-Johnson syndrome'. | Warfarin-induced Stevens-Johnson syndrome with severe liver injury.
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening mucocutaneous disease that is predominantly drug-induced. Warfarin is the most commonly used drug for long-term anti-coagulant therapy; however, warfarin-induced SJS/TE... | AMBROXOL, BUTORPHANOL, CEFOPERAZONE\SULBACTAM, CEFUROXIME, CEPHALOTHIN SODIUM, ENOXAPARIN, FUROSEMIDE, HALOPERIDOL, OLANZAPINE, RABEPRAZOLE, SPIRONOLACTONE, VANCOMYCIN, WARFARIN | DrugsGivenReaction | CC BY-NC | 34311601 | 19,709,776 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Toxic epidermal necrolysis'. | Warfarin-induced Stevens-Johnson syndrome with severe liver injury.
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening mucocutaneous disease that is predominantly drug-induced. Warfarin is the most commonly used drug for long-term anti-coagulant therapy; however, warfarin-induced SJS/TE... | AMBROXOL, BUTORPHANOL, CEFOPERAZONE\SULBACTAM, CEFUROXIME, CEPHALOTHIN SODIUM, ENOXAPARIN, FUROSEMIDE, HALOPERIDOL, OLANZAPINE, RABEPRAZOLE, SPIRONOLACTONE, VANCOMYCIN, WARFARIN | DrugsGivenReaction | CC BY-NC | 34311601 | 19,709,776 | 2021-07 |
What was the outcome of reaction 'Stevens-Johnson syndrome'? | Warfarin-induced Stevens-Johnson syndrome with severe liver injury.
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening mucocutaneous disease that is predominantly drug-induced. Warfarin is the most commonly used drug for long-term anti-coagulant therapy; however, warfarin-induced SJS/TE... | Recovered | ReactionOutcome | CC BY-NC | 34311601 | 19,709,776 | 2021-07 |
What was the outcome of reaction 'Toxic epidermal necrolysis'? | Warfarin-induced Stevens-Johnson syndrome with severe liver injury.
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening mucocutaneous disease that is predominantly drug-induced. Warfarin is the most commonly used drug for long-term anti-coagulant therapy; however, warfarin-induced SJS/TE... | Recovered | ReactionOutcome | CC BY-NC | 34311601 | 19,709,776 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebral haemorrhage'. | Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
BACKGROUND
Intravitreal injections of anti-vascular endothelial growth factor are commonly used to treat m... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 34311786 | 19,869,399 | 2021-07-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
BACKGROUND
Intravitreal injections of anti-vascular endothelial growth factor are commonly used to treat m... | AFLIBERCEPT | DrugsGivenReaction | CC BY | 34311786 | 19,869,399 | 2021-07-27 |
What was the administration route of drug 'AFLIBERCEPT'? | Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
BACKGROUND
Intravitreal injections of anti-vascular endothelial growth factor are commonly used to treat m... | Intraocular | DrugAdministrationRoute | CC BY | 34311786 | 19,869,399 | 2021-07-27 |
What was the outcome of reaction 'Cerebral haemorrhage'? | Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
BACKGROUND
Intravitreal injections of anti-vascular endothelial growth factor are commonly used to treat m... | Recovered | ReactionOutcome | CC BY | 34311786 | 19,869,399 | 2021-07-27 |
What was the outcome of reaction 'Hypertension'? | Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
BACKGROUND
Intravitreal injections of anti-vascular endothelial growth factor are commonly used to treat m... | Recovered | ReactionOutcome | CC BY | 34311786 | 19,869,399 | 2021-07-27 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bronchiolitis'. | Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
This study aimed to investigate the clinical manifestations, course and outcome of SARS-CoV-2 infection among children and... | ADALIMUMAB | DrugsGivenReaction | CC BY-NC | 34312307 | 20,169,667 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bronchitis'. | Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
This study aimed to investigate the clinical manifestations, course and outcome of SARS-CoV-2 infection among children and... | ADALIMUMAB | DrugsGivenReaction | CC BY-NC | 34312307 | 20,169,667 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19'. | Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
This study aimed to investigate the clinical manifestations, course and outcome of SARS-CoV-2 infection among children and... | ADALIMUMAB | DrugsGivenReaction | CC BY-NC | 34312307 | 20,169,667 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
This study aimed to investigate the clinical manifestations, course and outcome of SARS-CoV-2 infection among children and... | ADALIMUMAB | DrugsGivenReaction | CC BY-NC | 34312307 | 20,169,667 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
This study aimed to investigate the clinical manifestations, course and outcome of SARS-CoV-2 infection among children and... | ADALIMUMAB | DrugsGivenReaction | CC BY-NC | 34312307 | 20,169,667 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Uveitis'. | Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
This study aimed to investigate the clinical manifestations, course and outcome of SARS-CoV-2 infection among children and... | ADALIMUMAB | DrugsGivenReaction | CC BY-NC | 34312307 | 20,169,667 | 2021-07 |
What was the outcome of reaction 'Death'? | Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
This study aimed to investigate the clinical manifestations, course and outcome of SARS-CoV-2 infection among children and... | Fatal | ReactionOutcome | CC BY-NC | 34312307 | 20,169,667 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Basal cell carcinoma'. | Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by fibrosis of the skin and internal organs, autoimmunity-driven damage and vasculopathy. The current a... | METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 34313812 | 19,775,855 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by fibrosis of the skin and internal organs, autoimmunity-driven damage and vasculopathy. The current a... | METHOTREXATE, PREDNISONE | DrugsGivenReaction | CC BY | 34313812 | 19,775,855 | 2021-10 |
What was the administration route of drug 'METHOTREXATE'? | Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by fibrosis of the skin and internal organs, autoimmunity-driven damage and vasculopathy. The current a... | Oral | DrugAdministrationRoute | CC BY | 34313812 | 19,775,855 | 2021-10 |
What was the administration route of drug 'PREDNISONE'? | Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by fibrosis of the skin and internal organs, autoimmunity-driven damage and vasculopathy. The current a... | Oral | DrugAdministrationRoute | CC BY | 34313812 | 19,775,855 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.
BACKGROUND
Interstitial lung disease in rheumatoid arthritis (RA-ILD) is an extra-articular involvement that impairs the prognosis and for which there is still no well-coded treatment. The aim of t... | ABATACEPT | DrugsGivenReaction | CC BY | 34313866 | 19,711,950 | 2021-12 |
What was the administration route of drug 'ABATACEPT'? | Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.
BACKGROUND
Interstitial lung disease in rheumatoid arthritis (RA-ILD) is an extra-articular involvement that impairs the prognosis and for which there is still no well-coded treatment. The aim of t... | Subcutaneous | DrugAdministrationRoute | CC BY | 34313866 | 19,711,950 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acinetobacter infection'. | Unusual presentations of a severe type 2 leprosy reaction mimicking sepsis induced by helminth infection.
We describe an unusual case of type 2 leprosy reaction (T2R) with septic shock-like features induced by helminth infection in a 31-year-old Moluccan male patient with a history of completed treatment of WHO multidr... | PREDNISOLONE | DrugsGivenReaction | CC BY | 34314436 | 20,144,518 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bacteriuria'. | Unusual presentations of a severe type 2 leprosy reaction mimicking sepsis induced by helminth infection.
We describe an unusual case of type 2 leprosy reaction (T2R) with septic shock-like features induced by helminth infection in a 31-year-old Moluccan male patient with a history of completed treatment of WHO multidr... | PREDNISOLONE | DrugsGivenReaction | CC BY | 34314436 | 20,144,518 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disseminated intravascular coagulation'. | Unusual presentations of a severe type 2 leprosy reaction mimicking sepsis induced by helminth infection.
We describe an unusual case of type 2 leprosy reaction (T2R) with septic shock-like features induced by helminth infection in a 31-year-old Moluccan male patient with a history of completed treatment of WHO multidr... | PREDNISOLONE | DrugsGivenReaction | CC BY | 34314436 | 20,144,518 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastritis'. | Unusual presentations of a severe type 2 leprosy reaction mimicking sepsis induced by helminth infection.
We describe an unusual case of type 2 leprosy reaction (T2R) with septic shock-like features induced by helminth infection in a 31-year-old Moluccan male patient with a history of completed treatment of WHO multidr... | PREDNISOLONE | DrugsGivenReaction | CC BY | 34314436 | 20,144,518 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Helminthic infection'. | Unusual presentations of a severe type 2 leprosy reaction mimicking sepsis induced by helminth infection.
We describe an unusual case of type 2 leprosy reaction (T2R) with septic shock-like features induced by helminth infection in a 31-year-old Moluccan male patient with a history of completed treatment of WHO multidr... | PREDNISOLONE | DrugsGivenReaction | CC BY | 34314436 | 20,144,518 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hookworm infection'. | Unusual presentations of a severe type 2 leprosy reaction mimicking sepsis induced by helminth infection.
We describe an unusual case of type 2 leprosy reaction (T2R) with septic shock-like features induced by helminth infection in a 31-year-old Moluccan male patient with a history of completed treatment of WHO multidr... | PREDNISOLONE | DrugsGivenReaction | CC BY | 34314436 | 20,144,518 | 2021-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intentional product misuse'. | Unusual presentations of a severe type 2 leprosy reaction mimicking sepsis induced by helminth infection.
We describe an unusual case of type 2 leprosy reaction (T2R) with septic shock-like features induced by helminth infection in a 31-year-old Moluccan male patient with a history of completed treatment of WHO multidr... | PREDNISOLONE | DrugsGivenReaction | CC BY | 34314436 | 20,144,518 | 2021-07 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.